Illumina (NASDAQ:ILMN – Get Free Report) and Codexis (NASDAQ:CDXS – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.
Volatility & Risk
Illumina has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Codexis has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Illumina and Codexis, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Illumina | 2 | 7 | 9 | 0 | 2.39 |
| Codexis | 1 | 1 | 2 | 0 | 2.25 |
Earnings and Valuation
This table compares Illumina and Codexis”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Illumina | $4.49 billion | 7.33 | $850.00 million | $5.36 | 40.71 |
| Codexis | $70.39 million | 2.27 | -$43.97 million | ($0.34) | -4.29 |
Illumina has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
89.4% of Illumina shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 2.9% of Illumina shares are held by company insiders. Comparatively, 3.5% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Illumina and Codexis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Illumina | 18.36% | 29.84% | 12.17% |
| Codexis | -39.55% | -74.36% | -23.58% |
Summary
Illumina beats Codexis on 11 of the 14 factors compared between the two stocks.
About Illumina
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
About Codexis
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
